Derek Maetzold

Founder, President, and CEO

A leader in the biopharmaceutical industry for the past 25 years, Derek Maetzold founded Castle Biosciences in 2007 and has successfully overseen the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, with more in the pipeline. Derek founded the Company after a career of successive leadership roles at Encysive Pharmaceuticals, Schering Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals (now AstraZeneca) and Sandoz (now Novartis).

Derek started in field sales, and has served in roles that span the disciplines of marketing, new product development, business development, and commercialization strategy. Previously, he served as Officer and Vice President, Marketing and Sales, at Encysive Pharmaceuticals. He attended George Mason University, where he received a B.S. in Biology, and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at University of California-Riverside. Derek is a published author, and a co-inventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals.

Bernhard E. Spiess

Chief Operating Officer

Bernhard Spiess has over 35 years of clinical diagnostics experience most recently serving as Vice President of Product Management for both Clinical Chemistry and Infectious Diseases at Beckman Coulter. Throughout his career, Bernhard held positions of increasing responsibility in laboratory testing and management, scientific support, sales, strategic and tactical marketing, and product and business management. His primary focus over the last 20 years has been on immunoassay and molecular diagnostics. During his 23 years at Beckman Coulter, Bernhard played key leadership roles in the development and commercialization of a number of successful Beckman Coulter platforms. Earlier in his career he had global responsibility for the genomic services and molecular diagnostics sales teams at Beckman Coulter.

Bernhard started his career as a medical technologist before transitioning into scientific support and field sales with Abbott Diagnostics and Sanofi Diagnostics Pasteur. He attended the Royal Melbourne Institute of Technology, where he received a B.App.Sc. in Medical Technology.

Federico Monzon, M.D., FCAP

Chief Medical Officer

Federico A. Monzon is a molecular pathologist with extensive experience translating novel genomic technologies into clinical molecular tests. He is Chief Medical Officer at Castle Biosciences.  Prior to joining Castle, he served as Medical Director of Oncology and Medical Director of Latin America at Invitae Corporation, a provider of genetic diagnostics for hereditary disorders. Previously, Dr. Monzon served in several successive roles at Baylor College of Medicine, including Director of Pathology at its Cancer Genetics Laboratory. During his academic career, he led studies on prostate and renal cancer genomics as well as the validation of one of the first gene expression clinical assays for the diagnosis of tumors of unknown origin at the University of Pittsburgh and Houston Methodist Hospital. He earned his M.D. from the Universidad Nacional Autónoma de México, and is board-certified by the American Board of Pathology in anatomic, clinical and molecular genetic pathology. Dr. Monzon was the 2017 President of the Association for Molecular Pathology.

Frank Stokes

Chief Financial Officer

Frank Stokes has more than 20 years of experience in finance, including extensive experience leading capital formation for high-growth healthcare and life science companies.  Most recently he was CFO of Hammock Pharmaceuticals where he assisted in the initial capitalization of the company as well as the acquisition of Hammock’s foundational drug delivery technology.  Previously Frank served as a Senior Investment Banker at Leerink Partners, Robert W. Baird, and Wachovia Securities (now Wells Fargo Securities).  He received a B.S. in business administration followed by MBA and J.D. degrees from the University of North Carolina at Chapel Hill.

Toby Juvenal

Vice President, Sales

Toby Juvenal has over 20 years of sales, sales management, and managed care experience in the pharmaceutical, biotechnology and diagnostics industries. In his current role, Toby leads the Company’s sales efforts, and has been instrumental in the acceleration of sales growth in recent years.

Toby joined Castle Biosciences in 2008 as one of three initial employees. Prior to Castle, he held management positions at deCODE Genetics, Encysive Pharmaceuticals and Genzyme Pharmaceuticals. He began his career at Stuart Pharmaceuticals (now AstraZeneca). Toby attended the University of Florida where he received a B.S. in Marketing.

Kristen Oelschlager, RN

Vice President, Operations

Kristen Oelschlager joined the Company in 2008 as one of three initial employees, bringing more than 15 years of experience in clinical nursing, clinical operations services, and clinical research to the position. She oversees the operational aspects of the Company, including commercial/laboratory interface, clinical research and reimbursement. Prior to joining Castle, Kristen held senior roles in research operations, including the start-up and growth management of a multi-specialty clinical research department. She has extensive experience in process management under strict QA/QC/SOP.

Kristen attended Purdue University, where she completed core nursing requirements concurrent to receiving an Associate of Science, Nursing from the Indiana Vocational Technical College. She has held Speaker’s Bureau appointments for Actelion Pharmaceuticals, Eli Lilly, and Encysive Pharmaceuticals, is a published author, and a co-inventor of a number of Castle Biosciences’ technologies.

Robert W. Cook, PhD

Executive Director, Research and Development

Bob Cook has an extensive background in molecular biology and genetics, and over 15 years of experience in both academic and industry settings. Bob currently oversees research and development at Castle, including medical affairs. Bob’s initial discovery and development efforts at the Company have culminated in two commercially available technologies.

He joined Castle in 2011, following a postdoctoral fellowship at Baylor College of Medicine that was focused on the genetic regulation of rare ovarian granulosa cell tumors. Prior to pursuing his doctoral degree, he spent five years at Gen-Probe designing diagnostic assays using nucleic acid amplification technology.

Bob is a published author, and a co-inventor of a number of Castle Biosciences’ technologies. He received his B.S. Degree in Biology from Temple University in Philadelphia, and his PhD degree from Northwestern University for his studies of the structural characteristics of protein hormones important for regulating the reproductive system.

Greg Schafer

Executive Director, Managed Care

Greg Schafer has a strong background in managed care, sales and marketing, most recently serving as Head of Managed Care at Invitae Corporation, where he developed reimbursement and claims appeal strategy and increased in-network contracted providers. Previously, Greg served as Director of Strategic Markets and Associate Director of Managed Care at Genomic Health Inc., where he led managed care, field strategy and sales initiatives for the company’s oncology tests. Earlier in his career, Greg was Business Relations Manager at Biogen Inc., and held sales management roles at Novartis and Zeneca Pharmaceuticals. He graduated with honors from the University of Missouri with a B.S. in Agricultural Economics.

Noreen Manning

Director, Reimbursement

Noreen Manning joined Castle Biosciences with more than 11 years of experience in molecular diagnostics billing and reimbursement. In her current position, she oversees the billing operations, payer policy development and contracting. Prior to joining the Company, Noreen was the Associate Director of Reimbursement at Integrated Diagnostics, Inc. and an Account Executive at Quadax Inc. specializing in the design, implementation and development of reimbursement programs for start-up laboratories.